KR102857456B1 - 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 - Google Patents

인간 환자에서 자가-항원에 대한 예방접종을 위한 방법

Info

Publication number
KR102857456B1
KR102857456B1 KR1020187015512A KR20187015512A KR102857456B1 KR 102857456 B1 KR102857456 B1 KR 102857456B1 KR 1020187015512 A KR1020187015512 A KR 1020187015512A KR 20187015512 A KR20187015512 A KR 20187015512A KR 102857456 B1 KR102857456 B1 KR 102857456B1
Authority
KR
South Korea
Prior art keywords
vaccine
dose
autoantigen
antigen
boost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187015512A
Other languages
English (en)
Korean (ko)
Other versions
KR20180079406A (ko
Inventor
게르가나 가라보바
사빈 슈미트후버
아힘 슈네베르거
아르네 본 보닌
도리안 빈터
자나 짐머만
Original Assignee
에이씨 이뮨 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이씨 이뮨 에스에이 filed Critical 에이씨 이뮨 에스에이
Publication of KR20180079406A publication Critical patent/KR20180079406A/ko
Application granted granted Critical
Publication of KR102857456B1 publication Critical patent/KR102857456B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020187015512A 2015-11-03 2016-11-02 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 Active KR102857456B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192794 2015-11-03
EP15192794.4 2015-11-03
PCT/EP2016/076372 WO2017076873A1 (en) 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient

Publications (2)

Publication Number Publication Date
KR20180079406A KR20180079406A (ko) 2018-07-10
KR102857456B1 true KR102857456B1 (ko) 2025-09-08

Family

ID=54396782

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187015512A Active KR102857456B1 (ko) 2015-11-03 2016-11-02 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법

Country Status (10)

Country Link
US (1) US12290553B2 (enExample)
EP (1) EP3370761A1 (enExample)
JP (2) JP7378931B2 (enExample)
KR (1) KR102857456B1 (enExample)
CN (1) CN108472344A (enExample)
AU (1) AU2016348610B2 (enExample)
BR (1) BR112018008697A2 (enExample)
CA (1) CA3003943A1 (enExample)
RU (1) RU2734924C2 (enExample)
WO (1) WO2017076873A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472344A (zh) * 2015-11-03 2018-08-31 阿费里斯股份公司 用于针对人患者中的自身抗原的疫苗接种方法
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CA3100857A1 (en) * 2018-05-22 2019-11-28 The Governors Of The University Of Alberta Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
JP2023536497A (ja) 2020-08-04 2023-08-25 エイシー イミューン ソシエテ アノニム 免疫原性化合物
KR102527616B1 (ko) 2021-03-18 2023-05-02 정성욱 항체 관련 정보를 제공하는 방법 및 디바이스
IL314865A (en) 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
WO2025172592A1 (en) 2024-02-15 2025-08-21 Ac Immune Sa Alpha synuclein therapeutic vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101077416A (zh) 2002-10-23 2007-11-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
KR101512053B1 (ko) 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
MX374276B (es) 2014-02-28 2025-03-06 Affiris Cvd Gmbh Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
CN108472344A (zh) 2015-11-03 2018-08-31 阿费里斯股份公司 用于针对人患者中的自身抗原的疫苗接种方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope

Also Published As

Publication number Publication date
KR20180079406A (ko) 2018-07-10
EP3370761A1 (en) 2018-09-12
US12290553B2 (en) 2025-05-06
RU2018120009A3 (enExample) 2020-04-23
JP2018532782A (ja) 2018-11-08
JP7628333B2 (ja) 2025-02-10
AU2016348610B2 (en) 2023-08-31
JP2023175708A (ja) 2023-12-12
US20190091306A1 (en) 2019-03-28
AU2016348610A1 (en) 2018-05-10
BR112018008697A2 (en) 2018-10-30
JP7378931B2 (ja) 2023-11-14
RU2018120009A (ru) 2019-12-04
CA3003943A1 (en) 2017-05-11
RU2734924C2 (ru) 2020-10-26
CN108472344A (zh) 2018-08-31
WO2017076873A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
JP7628333B2 (ja) ヒト患者における自己抗原に対するワクチン接種法
Wang et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease
US11419924B2 (en) Immunotherapeutic compositions for the treatment of Alzheimer's disease
US20130287807A1 (en) Compounds for treating symptoms associated with parkinson's disease
US20150306194A1 (en) Method for treating a synucleiopathy
Maier et al. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G)
CN104411328A (zh) 组合物
JP2023536497A (ja) 免疫原性化合物
Ding et al. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice
Wang et al. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1 (A246E) transgenic mouse model of Alzheimer's disease
Myagkova et al. Vaccines for substance abuse treatment: New approaches in the immunotherapy of addictions
US20220218806A1 (en) Peptides and conjugates for treatment of arthritis
EA048154B1 (ru) Иммуногенные соединения
HK40087814A (zh) 免疫原性化合物
NZ744411A (en) Amyloid conjugate and uses and methods thereof
NZ744411B2 (en) Amyloid conjugate and uses and methods thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)